NT157 as an Anticancer Drug Candidate That Targets Kinase- and Phosphatase-Mediated Signaling
Abstract
:1. Introduction
2. Molecular Targets of NT157
3. Impact of NT157 on Cellular Processes in Experimental Cancer Models
4. Targeting the Tumor Microenvironment with NT157
5. Conclusions and Future Directions
Author Contributions
Funding
Conflicts of Interest
References
- Brown, J.S.; Amend, S.R.; Austin, R.H.; Gatenby, R.A.; Hammarlund, E.U.; Pienta, K.J. Updating the Definition of Cancer. Mol. Cancer Res. 2023, 21, 1142–1147. [Google Scholar] [CrossRef] [PubMed]
- Rossi, F.; Noren, H.; Jove, R.; Beljanski, V.; Grinnemo, K.H. Differences and similarities between cancer and somatic stem cells: Therapeutic implications. Stem Cell Res. Ther. 2020, 11, 489. [Google Scholar] [CrossRef] [PubMed]
- Hanahan, D.; Weinberg, R.A. The hallmarks of cancer. Cell 2000, 100, 57–70. [Google Scholar] [CrossRef] [PubMed]
- Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: The next generation. Cell 2011, 144, 646–674. [Google Scholar] [CrossRef] [PubMed]
- Hanahan, D. Hallmarks of Cancer: New Dimensions. Cancer Discov. 2022, 12, 31–46. [Google Scholar] [CrossRef] [PubMed]
- Bach, L.A. IGF-binding proteins. J. Mol. Endocrinol. 2018, 61, T11–T28. [Google Scholar] [CrossRef] [PubMed]
- Denduluri, S.K.; Idowu, O.; Wang, Z.; Liao, Z.; Yan, Z.; Mohammed, M.K.; Ye, J.; Wei, Q.; Wang, J.; Zhao, L.; et al. Insulin-like growth factor (IGF) signaling in tumorigenesis and the development of cancer drug resistance. Genes Dis. 2015, 2, 13–25. [Google Scholar] [CrossRef]
- Pellegrino, M.; Secli, V.; D’Amico, S.; Petrilli, L.L.; Caforio, M.; Folgiero, V.; Tumino, N.; Vacca, P.; Vinci, M.; Fruci, D.; et al. Manipulating the tumor immune microenvironment to improve cancer immunotherapy: IGF1R, a promising target. Front. Immunol. 2024, 15, 1356321. [Google Scholar] [CrossRef] [PubMed]
- Soni, U.K.; Jenny, L.; Hegde, R.S. IGF-1R targeting in cancer—Does sub-cellular localization matter? J. Exp. Clin. Cancer Res. 2023, 42, 273. [Google Scholar] [CrossRef]
- Machado-Neto, J.A.; Fenerich, B.A.; Rodrigues Alves AP, N.; Fernandes, J.C.; Scopim-Ribeiro, R.; Coelho-Silva, J.L.; Traina, F. Insulin Substrate Receptor (IRS) proteins in normal and malignant hematopoiesis. Clinics 2018, 73, e566s. [Google Scholar] [CrossRef]
- Wang, Z.; Li, W.; Guo, Q.; Wang, Y.; Ma, L.; Zhang, X. Insulin-Like Growth Factor-1 Signaling in Lung Development and Inflammatory Lung Diseases. Biomed. Res. Int. 2018, 2018, 6057589. [Google Scholar] [CrossRef] [PubMed]
- Guijarro, L.G.; Justo Bermejo, F.J.; Boaru, D.L.; De Castro-Martinez, P.; De Leon-Oliva, D.; Fraile-Martinez, O.; Garcia-Montero, C.; Alvarez-Mon, M.; Toledo-Lobo MD, V.; Ortega, M.A. Is Insulin Receptor Substrate4 (IRS4) a Platform Involved in the Activation of Several Oncogenes? Cancers 2023, 15, 4651. [Google Scholar] [CrossRef] [PubMed]
- Wortzel, I.; Seger, R. The ERK Cascade: Distinct Functions within Various Subcellular Organelles. Genes Cancer 2011, 2, 195–209. [Google Scholar] [CrossRef]
- Peng, Y.; Wang, Y.; Zhou, C.; Mei, W.; Zeng, C. PI3K/Akt/mTOR Pathway and Its Role in Cancer Therapeutics: Are We Making Headway? Front. Oncol. 2022, 12, 819128. [Google Scholar] [CrossRef] [PubMed]
- Wang, P.; Mak, V.C.; Cheung, L.W. Drugging IGF-1R in cancer: New insights and emerging opportunities. Genes Dis. 2023, 10, 199–211. [Google Scholar] [CrossRef] [PubMed]
- Chen, H.X.; Sharon, E. IGF-1R as an anti-cancer target—Trials and tribulations. Chin. J. Cancer 2013, 32, 242–252. [Google Scholar] [CrossRef] [PubMed]
- Weroha, S.J.; Haluska, P. IGF-1 receptor inhibitors in clinical trials—Early lessons. J. Mammary Gland Biol. Neoplasia 2008, 13, 471–483. [Google Scholar] [CrossRef] [PubMed]
- Beckwith, H.; Yee, D. Minireview: Were the IGF Signaling Inhibitors All Bad? Mol. Endocrinol. 2015, 29, 1549–1557. [Google Scholar] [CrossRef] [PubMed]
- Miao, Y.R.; Rankin, E.B.; Giaccia, A.J. Therapeutic targeting of the functionally elusive TAM receptor family. Nat. Rev. Drug Discov. 2024, 23, 201–217. [Google Scholar] [CrossRef]
- Mikolajczyk, A.; Mitula, F.; Popiel, D.; Kaminska, B.; Wieczorek, M.; Pieczykolan, J. Two-Front War on Cancer-Targeting TAM Receptors in Solid Tumour Therapy. Cancers 2022, 14, 2488. [Google Scholar] [CrossRef]
- DeRyckere, D.; Huelse, J.M.; Earp, H.S.; Graham, D.K. TAM family kinases as therapeutic targets at the interface of cancer and immunity. Nat. Rev. Clin. Oncol. 2023, 20, 755–779. [Google Scholar] [CrossRef]
- Reuveni, H.; Flashner-Abramson, E.; Steiner, L.; Makedonski, K.; Song, R.; Shir, A.; Herlyn, M.; Bar-Eli, M.; Levitzki, A. Therapeutic destruction of insulin receptor substrates for cancer treatment. Cancer Res. 2013, 73, 4383–4394. [Google Scholar] [CrossRef] [PubMed]
- Yaish, P.; Gazit, A.; Gilon, C.; Levitzki, A. Blocking of EGF-dependent cell proliferation by EGF receptor kinase inhibitors. Science 1988, 242, 933–935. [Google Scholar] [CrossRef]
- Levitzki, A.; Mishani, E. Tyrphostins and other tyrosine kinase inhibitors. Annu. Rev. Biochem. 2006, 75, 93–109. [Google Scholar] [CrossRef] [PubMed]
- Levitzki, A. Tyrosine kinases as targets for cancer therapy. Eur. J. Cancer 2002, 38 (Suppl. 5), S11–S18. [Google Scholar] [CrossRef]
- Goncalves, S.; Fernandez-Sanchez, R.; Sanchez-Nino, M.D.; Tejedor, A.; Neria, F.; Egido, J.; Ruiz-Ortega, M.; Ortiz, A. Tyrphostins as potential therapeutic agents for acute kidney injury. Curr. Med. Chem. 2010, 17, 974–986. [Google Scholar] [CrossRef] [PubMed]
- Caceres-Cortes, J.R. A potent anti-carcinoma and anti-acute myeloblastic leukemia agent, AG490. Anticancer Agents Med. Chem. 2008, 8, 717–722. [Google Scholar] [CrossRef] [PubMed]
- Flashner-Abramson, E.; Klein, S.; Mullin, G.; Shoshan, E.; Song, R.; Shir, A.; Langut, Y.; Bar-Eli, M.; Reuveni, H.; Levitzki, A. Targeting melanoma with NT157 by blocking Stat3 and IGF1R signaling. Oncogene 2016, 35, 2675–2680. [Google Scholar] [CrossRef]
- Su, S.P.; Flashner-Abramson, E.; Klein, S.; Gal, M.; Lee, R.S.; Wu, J.; Levitzki, A.; Daly, R.J. Impact of the Anticancer Drug NT157 on Tyrosine Kinase Signaling Networks. Mol. Cancer Ther. 2018, 17, 931–942. [Google Scholar] [CrossRef]
- Hiratani, K.; Haruta, T.; Tani, A.; Kawahara, J.; Usui, I.; Kobayashi, M. Roles of mTOR and JNK in serine phosphorylation, translocation, and degradation of IRS-1. Biochem. Biophys. Res. Commun. 2005, 335, 836–842. [Google Scholar] [CrossRef]
- Mardilovich, K.; Pankratz, S.L.; Shaw, L.M. Expression and function of the insulin receptor substrate proteins in cancer. Cell Commun. Signal. 2009, 7, 14. [Google Scholar] [CrossRef] [PubMed]
- de Miranda, L.B.L.; Lima, K.; Coelho-Silva, J.L.; Traina, F.; Kobayashi, S.S.; Machado-Neto, J.A. NT157 exerts antineoplastic activity by targeting JNK and AXL signaling in lung cancer cells. Sci. Rep. 2022, 12, 17092. [Google Scholar] [CrossRef]
- Fenerich, B.A.; Fernandes, J.C.; Rodrigues Alves AP, N.; Coelho-Silva, J.L.; Scopim-Ribeiro, R.; Scheucher, P.S.; Eide, C.A.; Tognon, C.E.; Druker, B.J.; Rego, E.M.; et al. NT157 has antineoplastic effects and inhibits IRS1/2 and STAT3/5 in JAK2(V617F)-positive myeloproliferative neoplasm cells. Signal Transduct. Target. Ther. 2020, 5, 5. [Google Scholar] [CrossRef] [PubMed]
- Kaliki, S.; Shields, C.L. Uveal melanoma: Relatively rare but deadly cancer. Eye 2017, 31, 241–257. [Google Scholar] [CrossRef]
- Chattopadhyay, C.; Bhattacharya, R.; Roszik, J.; Khan, F.S.; Wells, G.A.; Villanueva, H.; Qin, Y.; Patel, S.P.; Grimm, E.A. Targeting IRS-1/2 in Uveal Melanoma Inhibits In Vitro Cell Growth, Survival and Migration, and In Vivo Tumor Growth. Cancers 2022, 14, 6247. [Google Scholar] [CrossRef]
- Ibuki, N.; Ghaffari, M.; Reuveni, H.; Pandey, M.; Fazli, L.; Azuma, H.; Gleave, M.E.; Levitzki, A.; Cox, M.E. The tyrphostin NT157 suppresses insulin receptor substrates and augments therapeutic response of prostate cancer. Mol. Cancer Ther. 2014, 13, 2827–2839. [Google Scholar] [CrossRef]
- Garofalo, C.; Capristo, M.; Mancarella, C.; Reunevi, H.; Picci, P.; Scotlandi, K. Preclinical Effectiveness of Selective Inhibitor of IRS-1/2 NT157 in Osteosarcoma Cell Lines. Front. Endocrinol. 2015, 6, 74. [Google Scholar] [CrossRef] [PubMed]
- Sanchez-Lopez, E.; Flashner-Abramson, E.; Shalapour, S.; Zhong, Z.; Taniguchi, K.; Levitzki, A.; Karin, M. Targeting colorectal cancer via its microenvironment by inhibiting IGF-1 receptor-insulin receptor substrate and STAT3 signaling. Oncogene 2016, 35, 2634–2644. [Google Scholar] [CrossRef]
- Su, Y.; Zhao, A.; Cheng, G.; Xu, J.; Ji, E.; Sun, W. The IGF-I/JAK2-STAT3/miR-21 signaling pathway may be associated with human renal cell carcinoma cell growth. Cancer Biomark. 2017, 19, 289–296. [Google Scholar] [CrossRef]
- Ishii, H.; Vodnala, S.K.; Achyut, B.R.; So, J.Y.; Hollander, M.C.; Greten, T.F.; Lal, A.; Yang, L. miR-130a and miR-145 reprogram Gr-1(+)CD11b(+) myeloid cells and inhibit tumor metastasis through improved host immunity. Nat. Commun. 2018, 9, 2611. [Google Scholar] [CrossRef]
- Janse van Rensburg, H.J.; Lai, D.; Azad, T.; Hao, Y.; Yang, X. TAZ enhances mammary cell proliferation in 3D culture through transcriptional regulation of IRS1. Cell Signal. 2018, 52, 12–22. [Google Scholar] [CrossRef] [PubMed]
- Yang, Y.; Chan, J.Y.; Temiz, N.A.; Yee, D. Insulin Receptor Substrate Suppression by the Tyrphostin NT157 Inhibits Responses to Insulin-Like Growth Factor-I and Insulin in Breast Cancer Cells. Horm. Cancer 2018, 9, 371–382. [Google Scholar] [CrossRef]
- Shi, Y.; Ma, Z.; Cheng, Q.; Wu, Y.; Parris, A.B.; Kong, L.; Yang, X. FGFR1 overexpression renders breast cancer cells resistant to metformin through activation of IRS1/ERK signaling. Biochim. Biophys. Acta Mol. Cell Res. 2021, 1868, 118877. [Google Scholar] [CrossRef] [PubMed]
- Huggins, R.J.; Greene, G.L. ERalpha/PR crosstalk is altered in the context of the ERalpha Y537S mutation and contributes to endocrine therapy-resistant tumor proliferation. NPJ Breast Cancer 2023, 9, 96. [Google Scholar] [CrossRef] [PubMed]
- Su, C.; Wang, W.; Wang, C. IGF-1-induced MMP-11 expression promotes the proliferation and invasion of gastric cancer cells through the JAK1/STAT3 signaling pathway. Oncol. Lett. 2018, 15, 7000–7006. [Google Scholar] [CrossRef] [PubMed]
- Yu, S.; Wang, Y.; Lv, K.; Hou, J.; Li, W.; Wang, X.; Guo, H.; Wang, W. NT157 Inhibits HCC Migration via Downregulating the STAT3/Jab1 Signaling Pathway. Technol. Cancer Res. Treat. 2021, 20, 15330338211027916. [Google Scholar] [CrossRef] [PubMed]
- Zhang, J.; Mou, Y.; Li, H.; Shen, H.; Song, J.; Li, Q. LINC00638 promotes the progression of non-small cell lung cancer by regulating the miR-541-3p/IRS1/PI3K/Akt axis. Heliyon 2023, 9, e16999. [Google Scholar] [CrossRef] [PubMed]
- Hou, Y.J.; Li, D.; Wang, W.; Mao, L.; Fu, X.; Sun, B.; Fan, C. NT157 inhibits cell proliferation and sensitizes glioma cells to TRAIL-induced apoptosis by up-regulating DR5 expression. Biomed. Pharmacother. 2022, 153, 113502. [Google Scholar] [CrossRef]
- Li, C.X.; Men, C.D.; Yang, W.H.; Chen, R.; Zhu, J.H.; Cheng, Z.P. Repressing IRS1/2 by NT157 inhibits the malignant behaviors of ovarian cancer through inactivating PI3K/AKT/mTOR pathway and inducing autophagy. Kaohsiung J. Med. Sci. 2023, 39, 377–389. [Google Scholar] [CrossRef]
- Rodrigues Alves AP, N.; Fernandes, J.C.; Fenerich, B.A.; Coelho-Silva, J.L.; Scheucher, P.S.; Simoes, B.P.; Rego, E.M.; Ridley, A.J.; Machado-Neto, J.A.; Traina, F. IGF1R/IRS1 targeting has cytotoxic activity and inhibits PI3K/AKT/mTOR and MAPK signaling in acute lymphoblastic leukemia cells. Cancer Lett. 2019, 456, 59–68. [Google Scholar] [CrossRef]
- Fernandes, J.C.; Fenerich, B.A.; Alves-Silva, A.B.; Fonseca, N.P.; Coelho-Silva, J.L.; Scheucher, P.S.; Rego, E.M.; Figueiredo-Pontes, L.L.; Machado-Neto, J.A.; Traina, F. Differential cytotoxic activity of pharmacological inhibitors of IGF1R-related pathways in JAK2(V617F) driven cells. Toxicol In Vitro 2022, 83, 105384. [Google Scholar] [CrossRef]
- Scopim-Ribeiro, R.; Machado-Neto, J.A.; Eide, C.A.; Coelho-Silva, J.L.; Fenerich, B.A.; Fernandes, J.C.; Scheucher, P.S.; Savage Stevens, S.L.; de Melo Campos, P.; Olalla Saad, S.T.; et al. NT157, an IGF1R-IRS1/2 inhibitor, exhibits antineoplastic effects in pre-clinical models of chronic myeloid leukemia. Invest. New Drugs 2021, 39, 736–746. [Google Scholar] [CrossRef]
- Gao, Z.; Li, Z.; Li, X.; Xiao, J.; Li, C. Regulation of erythroid differentiation in K562 cells by the EPAS1-IRS2 axis under hypoxic conditions. Front. Cell Dev. Biol. 2023, 11, 1161541. [Google Scholar] [CrossRef]
- de Queiroz, G.N.; Lima, K.; de Miranda, L.B.L.; Rego, E.M.; Traina, F.; Machado-Neto, J.A. NT157 exhibits antineoplastic effects by targeting IRS and STAT3/5 signaling in multiple myeloma. Hematol. Transfus. Cell Ther. 2024. [Google Scholar] [CrossRef]
- Nicolini, F.E.; Mauro, M.J.; Martinelli, G.; Kim, D.W.; Soverini, S.; Muller, M.C.; Hochhaus, A.; Cortes, J.; Chuah, C.; Dufva, I.H.; et al. Epidemiologic study on survival of chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia patients with BCR-ABL T315I mutation. Blood 2009, 114, 5271–5278. [Google Scholar] [CrossRef]
- Owen, K.L.; Brockwell, N.K.; Parker, B.S. JAK-STAT Signaling: A Double-Edged Sword of Immune Regulation and Cancer Progression. Cancers 2019, 11, 2002. [Google Scholar] [CrossRef] [PubMed]
- Rah, B.; Rather, R.A.; Bhat, G.R.; Baba, A.B.; Mushtaq, I.; Farooq, M.; Yousuf, T.; Dar, S.B.; Parveen, S.; Hassan, R.; et al. JAK/STAT Signaling: Molecular Targets, Therapeutic Opportunities, and Limitations of Targeted Inhibitions in Solid Malignancies. Front. Pharmacol. 2022, 13, 821344. [Google Scholar] [CrossRef] [PubMed]
- Hu, X.; Li, J.; Fu, M.; Zhao, X.; Wang, W. The JAK/STAT signaling pathway: From bench to clinic. Signal Transduct. Target. Ther. 2021, 6, 402. [Google Scholar] [CrossRef] [PubMed]
- Sabaawy, H.E.; Ryan, B.M.; Khiabanian, H.; Pine, S.R. JAK/STAT of all trades: Linking inflammation with cancer development, tumor progression and therapy resistance. Carcinogenesis 2021, 42, 1411–1419. [Google Scholar] [CrossRef]
- Axelrod, H.; Pienta, K.J. Axl as a mediator of cellular growth and survival. Oncotarget 2014, 5, 8818–8852. [Google Scholar] [CrossRef]
- Goyette, M.A.; Cote, J.F. AXL Receptor Tyrosine Kinase as a Promising Therapeutic Target Directing Multiple Aspects of Cancer Progression and Metastasis. Cancers 2022, 14, 466. [Google Scholar] [CrossRef] [PubMed]
- Wium, M.; Ajayi-Smith, A.F.; Paccez, J.D.; Zerbini, L.F. The Role of the Receptor Tyrosine Kinase Axl in Carcinogenesis and Development of Therapeutic Resistance: An Overview of Molecular Mechanisms and Future Applications. Cancers 2021, 13, 1521. [Google Scholar] [CrossRef] [PubMed]
- Linger, R.M.; Keating, A.K.; Earp, H.S.; Graham, D.K. TAM receptor tyrosine kinases: Biologic functions, signaling, and potential therapeutic targeting in human cancer. Adv. Cancer Res. 2008, 100, 35–83. [Google Scholar] [PubMed]
- Liu, Z.; Chen, L.; Zhang, J.; Yang, J.; Xiao, X.; Shan, L.; Mao, W. Recent discovery and development of AXL inhibitors as antitumor agents. Eur. J. Med. Chem. 2024, 272, 116475. [Google Scholar] [CrossRef]
- De Rosa, L.; Di Stasi, R.; Fusco, V.; D’Andrea, L.D. AXL receptor as an emerging molecular target in colorectal cancer. Drug Discov. Today 2024, 29, 104005. [Google Scholar] [CrossRef]
Cancer Type | Experimental Models | NT157’s Potency | NT157’s Molecular Targets | NT157’s Cellular Effects | Reference |
---|---|---|---|---|---|
Melanoma | Multiple models * | IC50: 0.3–1 μM (72 h) | IRS1 and IRS2 | Reduction in in vitro cell viability and migration, as well as in vivo tumor growth and lung metastasis. | [22] |
Prostate cancer | LNCaP, PC3, and normal prostatic fibroblasts | IC50: 1.4–2.5 μM (72 h) | IRS1 and IRS2 | Reduction in cell viability, cell cycle arrest, and in vivo tumor growth. | [36] |
Osteosarcoma | U-2OS, OS19, and MG-63 cells | IC50: 0.3–0.8 μM (72 h) | IRS1 and IRS2 | Reduction in cell proliferation and migration and cell cycle. | [37] |
Melanoma | Multiple models ** | IC50: 0.28 μM (72 h) | IRS1, IRS2, and STAT3 | Reduction in cell viability and angiogenesis. | [28] |
Colorectal cancer | HCT-116, SW620, HT-29, SW4-80, DLD-1, and MC-38 cells | Not determined | IRS1, IRS2, and STAT3 | Reduction in cell migration, in vivo tumor growth, and metastasis. | [38] |
Renal cell carcinoma | A-498, ACHN, Caki-1, Caki-2 77, and 786-O cells | Not determined | IGF1 signaling and STAT3 | Attenuation in IGF1-induced cell proliferation. | [39] |
Breast cancer | 4T1 and E0771 cells | Not determined | IRS1 | Reduction in in vivo metastasis. | [40] |
Breast cancer | MCF 10A cells | Not determined | IRS1 | Reduction in 3D cell proliferation. | [41] |
Gastric cancer | SGC-7901 cells | Not determined | IGF1 signaling and STAT3 | Reduction in cell proliferation and invasion. | [45] |
Breast cancer | MCF7, T-47D, and MDA-MB-231 cells | Not determined | IRS1 and IRS2 | Reduction in cell proliferation and colony formation. | [42] |
Acute lymphoblastic leukemia | Jurkat, MOLT-4, Namalwa, Raji, and primary leukocytes from healthy donors and ALL patients | IC50: 0.3–1.9 μM (72 h) | IGF1R and IRS1 | Reduction in cell viability, proliferation, migration, and induction of cell cycle arrest and apoptosis. | [50] |
Myeloproliferative neoplasm | HEL, SET-2, and primary cells from MPN patients | IC50: 0.68–>3.2 μM (72 h) | IRS1, IRS2, STAT3, and STAT5 | Reduction in cell viability, proliferation, clonal growth, and induction of cell cycle arrest and apoptosis. | [33] |
Chronic myeloid leukemia | K-562, Ba/F3 expressing BCR::ABL1 and BCR::ABL1T315I, and primary cells from CML patients. | IC50: 0.3–0.68 μM (48 and 72 h) | IRS1 and IRS2 | Reduction in cell viability, proliferation, clonal growth, and induction of cell cycle arrest and apoptosis. | [52] |
Breast cancer | MCF7 and T-47D | Not determined | IRS1 | Reduction in clonal growth. | [43] |
Hepatocellular carcinoma | HUH-7, MHCC-97 H, SMMC-7721, MHCC97-L, and HepG2 cells | Not determined | STAT3 | Inhibition of migration in vitro and lung metastasis in vivo. | [46] |
Uveal Melanoma | Mel20–06–039, OMM-1, Mel202, 92–1, Mel270, MM28, MP38, MP41, BJ fibroblasts, HaCaT, and HEMn cells | Not determined | IRS1 and IRS2 | Reduction in in vitro cell growth, survival, and migration, as well as in vivo tumor growth. | [35] |
Lung cancer | NCI-H1299, NCI-H460, and NCI-H1975 cells | IC50: 1.8–4.8 μM (72 h) | IRS1, IRS2, JNK, and AXL | Reduction in cell viability, clonal growth, migration, and induction of cell cycle arrest and apoptosis. | [32] |
Myeloproliferative neoplasm | Ba/F3 expressing JAK2V617F cells | IC50: 0.8 μM (48 h) | IRS1, IRS2, STAT3, and STAT5 | Reduction in cell viability, proliferation, and induction of apoptosis. | [51] |
Glioma | U-87 MG and U-251 MG cells | IC50: >40 μM (24 h) | STAT3 | Reduction in cell viability, survival, cell cycle progression, and migration, as well as in vivo tumor growth. | [48] |
Chronic myeloid leukemia | K-562 cells | Not determined | IRS2 | Inhibition of erythroid differentiation induced by hypoxia. | [53] |
Breast cancer | MCF7 and T-47D cells | Not determined | IRS1 | Reduction in cell proliferation. | [44] |
Ovarian cancer | OVCAR-3 and OVCA433 cells | IC50: >3.2 μM (24 h) | IRS1 and IRS2 | Reduction in cell viability, proliferation, clonal growth, invasion, and induction of apoptosis and autophagy. | [49] |
Lung cancer | BEAS-2B, HCC-827, A549, NCI–H460, NCI-NCI-H1975, NCI-H1299, and H460 cells | Not determined | IRS1 | Inhibition of migration, invasion, and epithelial-mesenchymal transition. | [47] |
Multiple myeloma | MM.1S, MM.1R, U266, and RPMI 8226 cells | IC50: 2.6–18.5 μM (72 h) | IRS2, STAT3, and STAT5 | Reduction in cell viability, clonal growth, and induction of cell cycle arrest and apoptosis. | [54] |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Lima, K.; Machado-Neto, J.A. NT157 as an Anticancer Drug Candidate That Targets Kinase- and Phosphatase-Mediated Signaling. Kinases Phosphatases 2024, 2, 179-189. https://0-doi-org.brum.beds.ac.uk/10.3390/kinasesphosphatases2020011
Lima K, Machado-Neto JA. NT157 as an Anticancer Drug Candidate That Targets Kinase- and Phosphatase-Mediated Signaling. Kinases and Phosphatases. 2024; 2(2):179-189. https://0-doi-org.brum.beds.ac.uk/10.3390/kinasesphosphatases2020011
Chicago/Turabian StyleLima, Keli, and João Agostinho Machado-Neto. 2024. "NT157 as an Anticancer Drug Candidate That Targets Kinase- and Phosphatase-Mediated Signaling" Kinases and Phosphatases 2, no. 2: 179-189. https://0-doi-org.brum.beds.ac.uk/10.3390/kinasesphosphatases2020011